Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?

Sabrina Valeria Porta; Manuel F. Ugarte-Gil; Ignacio Garciá-De La Torre; Eloísa Bonfá; José A. Gómez-Puerta; Laurent Arnaud; Mario H. Cardiel; Graciela S. Alarcón; Bernardo A. Pons-Estel; Guillermo Pons-Estel

doi:10.1097/RHU.0000000000001803

Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?

Sabrina Valeria Porta, Manuel F. Ugarte-Gil, Ignacio Garciá-De La Torre, Eloísa Bonfá, José A. Gómez-Puerta, Laurent Arnaud, Mario H. Cardiel, Graciela S. Alarcón, Bernardo A. Pons-Estel, Guillermo Pons-Estel

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Systemic lupus erythematosus (SLE) is characterized by great clinical heterogeneity. The objectives of its management are to make a timely diagnosis and to initiate treatment as promptly as possible so organ damage can be avoided while at the same time exposure to potentially toxic drugs is minimized so that its overall course and outcome improve. In reviewing the current literature, it became quite clear that there are specific topics in which controversies do exist. These include how to treat patients with incomplete lupus erythematosus, the real possibility of abandoning altogether the use of oral glucocorticoids, and the pros and cons of the use of cyclophosphamide and mycophenolate mofetil for the induction treatment of lupus nephritis. Herein we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the PANLAR Virtual Congress (Pan American League of Associations for Rheumatology) and that was organized by the PANLAR Lupus study group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on September 19, 2020.

Original language	English
Pages (from-to)	E651-E658
Journal	Journal of Clinical Rheumatology
Volume	28
Issue number	2
DOIs	https://doi.org/10.1097/RHU.0000000000001803
State	Published - 1 Mar 2022

Bibliographical note

Funding Information:
M.F.U.-G. has received research grants from Pfizer and Janssen. J.A.G.-P. has received less than US $10,000 in speaking fees from GSK, Janssen, Lilly Pfizer, and Roche. L.A. has received consulting/research grants from Alexion, Amgen, Astra-Zeneca, BMS, Boehringer-Ingelheim, GSK, Grifols, Janssen-Cilag, LFB, Lilly, Medac, Novartis, Pfizer, Roche-Chugaï, and UCB. M.H.C. is principal investigator of or advisor or speaker for Abbvie, Amgen, Astra Zéneca, Eli Lilly, Gilead, Glaxo Smith Kline, Janssen, Pfizer, and Roche. The other authors declare no conflict of interest.

Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.

Keywords

cyclophosphamide
glucocorticoids
incomplete lupus
lupus nephritis
mycophenolate
systemic lupus erythematosus
treatment

Access to Document

10.1097/RHU.0000000000001803

Cite this

@article{0f4a74c1b54c4a3da9bdaaff1c74ac3d,

title = "Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?",

abstract = "Systemic lupus erythematosus (SLE) is characterized by great clinical heterogeneity. The objectives of its management are to make a timely diagnosis and to initiate treatment as promptly as possible so organ damage can be avoided while at the same time exposure to potentially toxic drugs is minimized so that its overall course and outcome improve. In reviewing the current literature, it became quite clear that there are specific topics in which controversies do exist. These include how to treat patients with incomplete lupus erythematosus, the real possibility of abandoning altogether the use of oral glucocorticoids, and the pros and cons of the use of cyclophosphamide and mycophenolate mofetil for the induction treatment of lupus nephritis. Herein we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the PANLAR Virtual Congress (Pan American League of Associations for Rheumatology) and that was organized by the PANLAR Lupus study group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on September 19, 2020.",

keywords = "cyclophosphamide, glucocorticoids, incomplete lupus, lupus nephritis, mycophenolate, systemic lupus erythematosus, treatment",

author = "Porta, {Sabrina Valeria} and Ugarte-Gil, {Manuel F.} and {Garci{\'a}-De La Torre}, Ignacio and Elo{\'i}sa Bonf{\'a} and G{\'o}mez-Puerta, {Jos{\'e} A.} and Laurent Arnaud and Cardiel, {Mario H.} and Alarc{\'o}n, {Graciela S.} and Pons-Estel, {Bernardo A.} and Guillermo Pons-Estel",

year = "2022",

month = mar,

day = "1",

doi = "10.1097/RHU.0000000000001803",

language = "Ingl{\'e}s",

volume = "28",

pages = "E651--E658",

journal = "Journal of Clinical Rheumatology",

issn = "1076-1608",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "2",

}

TY - JOUR

T1 - Controversies in Systemic Lupus Erythematosus

T2 - Are We Treating Our Patients Adequately?

AU - Porta, Sabrina Valeria

AU - Ugarte-Gil, Manuel F.

AU - Garciá-De La Torre, Ignacio

AU - Bonfá, Eloísa

AU - Gómez-Puerta, José A.

AU - Arnaud, Laurent

AU - Cardiel, Mario H.

AU - Alarcón, Graciela S.

AU - Pons-Estel, Bernardo A.

AU - Pons-Estel, Guillermo

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Systemic lupus erythematosus (SLE) is characterized by great clinical heterogeneity. The objectives of its management are to make a timely diagnosis and to initiate treatment as promptly as possible so organ damage can be avoided while at the same time exposure to potentially toxic drugs is minimized so that its overall course and outcome improve. In reviewing the current literature, it became quite clear that there are specific topics in which controversies do exist. These include how to treat patients with incomplete lupus erythematosus, the real possibility of abandoning altogether the use of oral glucocorticoids, and the pros and cons of the use of cyclophosphamide and mycophenolate mofetil for the induction treatment of lupus nephritis. Herein we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the PANLAR Virtual Congress (Pan American League of Associations for Rheumatology) and that was organized by the PANLAR Lupus study group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on September 19, 2020.

AB - Systemic lupus erythematosus (SLE) is characterized by great clinical heterogeneity. The objectives of its management are to make a timely diagnosis and to initiate treatment as promptly as possible so organ damage can be avoided while at the same time exposure to potentially toxic drugs is minimized so that its overall course and outcome improve. In reviewing the current literature, it became quite clear that there are specific topics in which controversies do exist. These include how to treat patients with incomplete lupus erythematosus, the real possibility of abandoning altogether the use of oral glucocorticoids, and the pros and cons of the use of cyclophosphamide and mycophenolate mofetil for the induction treatment of lupus nephritis. Herein we discuss different points of view regarding these still unresolved issues; these comments represent a debate that took place during the PANLAR Virtual Congress (Pan American League of Associations for Rheumatology) and that was organized by the PANLAR Lupus study group, GLADEL (Grupo Latino Americano De Estudio del Lupus) on September 19, 2020.

KW - cyclophosphamide

KW - glucocorticoids

KW - incomplete lupus

KW - lupus nephritis

KW - mycophenolate

KW - systemic lupus erythematosus

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85125016501&partnerID=8YFLogxK

U2 - 10.1097/RHU.0000000000001803

DO - 10.1097/RHU.0000000000001803

M3 - Artículo

C2 - 34897194

AN - SCOPUS:85125016501

SN - 1076-1608

VL - 28

SP - E651-E658

JO - Journal of Clinical Rheumatology

JF - Journal of Clinical Rheumatology

IS - 2

ER -

Controversies in Systemic Lupus Erythematosus: Are We Treating Our Patients Adequately?

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this